Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 4
2012 11
2013 12
2014 18
2015 27
2016 25
2017 27
2018 23
2019 18
2020 29
2021 38
2022 24
2023 32
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.
Liu Z, Xue J, Deng Q, Wang Y, Zhang L, Liu L, Xiao N, Chang T, Cui Y, Cheng Y, Liu G, Wang W, Zhou Y, Yang W, Qu X, Chen J, Zhao Y, Wang Z, Yang H. Liu Z, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 21. doi: 10.1007/s00210-024-03055-1. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38643450
Latuda() is a novel antipsychotic drug for schizophrenia and bipolar depression. A bioequivalence trial was performed to investigate the bioequivalence of Latuda() and its generic drug lurasidone. ...The results displayed that lurasidone and Latuda() were bio …
Latuda() is a novel antipsychotic drug for schizophrenia and bipolar depression. A bioequivalence trial was performed to investigate …
Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode: A Post Hoc Analysis of 2 Placebo-Controlled Trials.
Tocco M, Mao Y. Tocco M, et al. J Clin Psychopharmacol. 2024 Apr 19. doi: 10.1097/JCP.0000000000001850. Online ahead of print. J Clin Psychopharmacol. 2024. PMID: 38639433
PURPOSE: The aim of this study was to compare the efficacy and safety profile of lurasidone combined with either lithium or valproate, in the short-term treatment of patients with bipolar depression. ...Minimal changes in weight, lipids, and measures of glycemic con …
PURPOSE: The aim of this study was to compare the efficacy and safety profile of lurasidone combined with either lithium or valproate …
Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials.
Kong L, Wang H, Yan N, Xu C, Chen Y, Zeng Y, Guo X, Lu J, Hu S. Kong L, et al. EClinicalMedicine. 2024 Apr 5;71:102581. doi: 10.1016/j.eclinm.2024.102581. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38618207 Free PMC article.
After eliminating possible sensitivity, risperidone ranked 1st in elevating fasting serum glucose (SUCRA = 90.7%) and serum insulin (SUCRA = 96.6%). Lurasidone was most likely to elevate HbA1c (SUCRA = 82.1%). Olanzapine ranked 1st in elevating serum TC (SUCRA = 93.3%), TG …
After eliminating possible sensitivity, risperidone ranked 1st in elevating fasting serum glucose (SUCRA = 90.7%) and serum insulin (SUCRA = …
Drugs for bipolar disorder.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54. doi: 10.58347/tml.2024.1699a. Med Lett Drugs Ther. 2024. PMID: 38576143 No abstract available.
Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis.
Li S, Xu C, Hu S, Lai J. Li S, et al. Eur Psychiatry. 2024 Mar 15;67(1):e29. doi: 10.1192/j.eurpsy.2024.25. Eur Psychiatry. 2024. PMID: 38487836 Free PMC article. Review.
We employed a Bayesian network meta-analysis for comparison of the efficacy and tolerability of US Food and Drug Administration (FDA)-approved atypical antipsychotics (AAPs) for the treatment of bipolar patients with depressive episodes. Sixteen randomized controlled trial …
We employed a Bayesian network meta-analysis for comparison of the efficacy and tolerability of US Food and Drug Administration (FDA)-approv …
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data.
Fountoulakis KN, Tohen M, Zarate CA Jr. Fountoulakis KN, et al. Eur Neuropsychopharmacol. 2024 Apr;81:1-9. doi: 10.1016/j.euroneuro.2024.01.002. Epub 2024 Feb 3. Eur Neuropsychopharmacol. 2024. PMID: 38310714 Review.
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. ...The neurobiology of bipolar depression and the possible mechanistic targets of bipolar antidepressant therapy remain elusive. ...
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. ...The neurobiology of bipola …
Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.
Feng XZ, Li Z, Li ZY, Wang K, Tan X, Zhao YY, Mi WF, Zhu WL, Bao YP, Lu L, Li SX. Feng XZ, et al. Psychiatry Res. 2024 Feb;332:115637. doi: 10.1016/j.psychres.2023.115637. Epub 2023 Dec 2. Psychiatry Res. 2024. PMID: 38150810
All SGAs showed significant effects in treating other mental disorders compared with placebo, except autistic disorder and dementia. Aripiprazole is the most effective treatment for bipolar mania [effect size = -0.90, 95% CI: -1.59, -0.21] and Tourette's disorder [effect s …
All SGAs showed significant effects in treating other mental disorders compared with placebo, except autistic disorder and dementia. Aripipr …
Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients.
Okura S, Deguchi Y, Cho T, Kageyama Y, Inoue K. Okura S, et al. Cureus. 2023 Nov 18;15(11):e49005. doi: 10.7759/cureus.49005. eCollection 2023 Nov. Cureus. 2023. PMID: 38111448 Free PMC article.
Unhealthy lifestyles such as reduced physical activity, sleep disturbances, and irregular diets can lead to weight gain. Herein, we report two cases of schizophrenia and bipolar disorder who had a 10-kg gain in weight in six months with the administration of lurasidone …
Unhealthy lifestyles such as reduced physical activity, sleep disturbances, and irregular diets can lead to weight gain. Herein, we report t …
The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes.
Danek PJ, Daniel WA. Danek PJ, et al. Int J Mol Sci. 2023 Nov 27;24(23):16796. doi: 10.3390/ijms242316796. Int J Mol Sci. 2023. PMID: 38069119 Free PMC article.
Lurasidone is a novel atypical antipsychotic drug acting on dopaminergic, serotonergic and noradrenergic receptors; it is applied for the long-term treatment of schizophrenia and depression in patients with bipolar disorders. ...At the same time, lurasidone d …
Lurasidone is a novel atypical antipsychotic drug acting on dopaminergic, serotonergic and noradrenergic receptors; it is applied for …
Transcranial Magnetic Stimulation in Bipolar II Disorder Treatment: A Case Report.
Tran NN, Hutto S, Thompson LR, Hawkins A. Tran NN, et al. Cureus. 2023 Sep 25;15(9):e45918. doi: 10.7759/cureus.45918. eCollection 2023 Sep. Cureus. 2023. PMID: 37885535 Free PMC article.
The objective of this case report is to describe and document the use of transcranial magnetic stimulation (TMS) to aid in the treatment of bipolar II disorder. A 35-year-old male with a past medical history of attention-deficit/hyperactivity disorder (ADHD), post-traumati …
The objective of this case report is to describe and document the use of transcranial magnetic stimulation (TMS) to aid in the treatment of …
Transcriptomic analyses of rats exposed to chronic mild stress: Modulation by chronic treatment with the antipsychotic drug lurasidone.
Begni V, Marizzoni M, Creutzberg KC, Silipo DM, Papp M, Cattaneo A, Riva MA. Begni V, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Feb 8;129:110885. doi: 10.1016/j.pnpbp.2023.110885. Epub 2023 Oct 20. Prog Neuropsychopharmacol Biol Psychiatry. 2024. PMID: 37865392 Free article.
However, the mechanisms that may contribute to the therapeutic effects of lurasidone are still poorly understood. Here, we performed a transcriptomic analysis on the prefrontal cortex (PFC) of adult male rats exposed to the chronic mild stress (CMS) paradigm and we investi …
However, the mechanisms that may contribute to the therapeutic effects of lurasidone are still poorly understood. Here, we performed …
Diagnosis and Treatment of Bipolar Disorder: A Review.
Nierenberg AA, Agustini B, Köhler-Forsberg O, Cusin C, Katz D, Sylvia LG, Peters A, Berk M. Nierenberg AA, et al. JAMA. 2023 Oct 10;330(14):1370-1380. doi: 10.1001/jama.2023.18588. JAMA. 2023. PMID: 37815563 Review.
Bipolar depressive episodes are similar to major depressive episodes. ...Approximately 15% to 20% of people with bipolar disorder die by suicide. CONCLUSIONS AND RELEVANCE: Bipolar disorder affects approximately 8 million adults in the US. ...
Bipolar depressive episodes are similar to major depressive episodes. ...Approximately 15% to 20% of people with bipolar disor …
Lurasidone blocks the voltage-gated potassium channels of coronary arterial smooth muscle cells.
Zhuang W, Mun SY, Park M, Jeong J, Park H, Na S, Lee SJ, Jung WK, Choi IW, Li H, Park WS. Zhuang W, et al. Eur J Pharmacol. 2023 Oct 15;957:176005. doi: 10.1016/j.ejphar.2023.176005. Epub 2023 Aug 21. Eur J Pharmacol. 2023. PMID: 37611842
Lurasidone is a second-generation antipsychotic drug used to treat schizophrenia, mania, and bipolar disorder. ...These results suggest that the inhibitory action of lurasidone is use (state)-dependent. Pretreatment with a Kv 1.5 subtype inhibitor effectively …
Lurasidone is a second-generation antipsychotic drug used to treat schizophrenia, mania, and bipolar disorder. ...These result …
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Yildiz A, et al. Lancet Psychiatry. 2023 Sep;10(9):693-705. doi: 10.1016/S2215-0366(23)00199-2. Lancet Psychiatry. 2023. PMID: 37595997
BACKGROUND: Bipolar depression constitutes a major public health problem due to its substantial burden of disease. ...INTERPRETATION: This is, to our knowledge, the largest network meta-analysis of pharmacotherapy for bipolar depression to date. Olanzapine plus fluo …
BACKGROUND: Bipolar depression constitutes a major public health problem due to its substantial burden of disease. ...INTERPRETATION: …
NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial.
Nierenberg A, Lavin P, Javitt DC, Shelton R, Sapko MT, Mathew S, Besthof RE, Javitt JC. Nierenberg A, et al. Int J Bipolar Disord. 2023 Aug 13;11(1):28. doi: 10.1186/s40345-023-00308-5. Int J Bipolar Disord. 2023. PMID: 37573534 Free PMC article.
BACKGROUND: We tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloserine (DCS) and lurasidone …
BACKGROUND: We tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) …
Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis.
Garcia-Rodriguez L, Burton DJ, Leonards CA, Davey CG. Garcia-Rodriguez L, et al. J Affect Disord. 2023 Oct 15;339:633-639. doi: 10.1016/j.jad.2023.07.082. Epub 2023 Jul 17. J Affect Disord. 2023. PMID: 37467794 Free article. Review.
RESULTS: No studies were identified that evaluated the use of antipsychotics in the treatment of unipolar depression. However, we identified four studies, of quetiapine, lurasidone and olanzapine/fluoxetine combination, comprising a total of 866 randomized patients, that e …
RESULTS: No studies were identified that evaluated the use of antipsychotics in the treatment of unipolar depression. However, we identified …
The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis.
Goldberg JF, Siu C, Tocco M, Pikalov A, Loebel A. Goldberg JF, et al. J Clin Psychiatry. 2023 Jun 7;84(4):22m14732. doi: 10.4088/JCP.22m14732. J Clin Psychiatry. 2023. PMID: 37339360 Free article.
Objective: To assess the effects of lurasidone on anxiety symptoms and sleep disruption, and their moderating and mediating roles on treatment response in bipolar depression. ...Decrease in sleep at baseline predicted change in anxiety symptoms with lurasidone …
Objective: To assess the effects of lurasidone on anxiety symptoms and sleep disruption, and their moderating and mediating roles on …
Lurasidone.
Azhar Y, Shaban K. Azhar Y, et al. 2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31082101 Free Books & Documents.
Lurasidone is a medication used in the treatment of schizophrenia and bipolar depression. ...This activity describes the indications, action, and contraindications for lurasidone as a valuable agent in treating schizophrenia and bipolar depression. ...
Lurasidone is a medication used in the treatment of schizophrenia and bipolar depression. ...This activity describes the indic …
Lurasidone.
[No authors listed] [No authors listed] 2023 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643626 Free Books & Documents. Review.
Lurasidone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia and bipolar depression. Lurasidone is associated with a low rate of serum aminotransferase elevations during therapy but has not been linked to ins …
Lurasidone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia and bipolar de …
The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials.
Kato M, Masuda T, Sano F, Kato T. Kato M, et al. J Affect Disord. 2023 Sep 15;337:150-158. doi: 10.1016/j.jad.2023.05.065. Epub 2023 May 26. J Affect Disord. 2023. PMID: 37245552 Free article. Clinical Trial.
BACKGROUND: The efficacy and safety of lurasidone monotherapy in patients with bipolar I depression with or without rapid cycling has not been previously investigated. ...LIMITATIONS: This was a post-hoc analysis of a short-term study that excluded patients with 8 c …
BACKGROUND: The efficacy and safety of lurasidone monotherapy in patients with bipolar I depression with or without rapid cycl …
Mood Stabilizers of First and Second Generation.
Rybakowski JK. Rybakowski JK. Brain Sci. 2023 Apr 29;13(5):741. doi: 10.3390/brainsci13050741. Brain Sci. 2023. PMID: 37239213 Free PMC article. Review.
Recently, as a candidate for SGMSs, a novel antipsychotic, lurasidone, has been suggested. Several other atypical antipsychotics, anticonvulsants, and memantine showed some usefulness in the treatment and prophylaxis of bipolar disorder; however, they do not fully m …
Recently, as a candidate for SGMSs, a novel antipsychotic, lurasidone, has been suggested. Several other atypical antipsychotics, ant …
Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy.
Tarzian M, Soudan M, Alhajji M, Ndrio M, Fakoya AO. Tarzian M, et al. Cureus. 2023 Apr 24;15(4):e38071. doi: 10.7759/cureus.38071. eCollection 2023 Apr. Cureus. 2023. PMID: 37228542 Free PMC article. Review.
It has rapid absorption and linear pharmacokinetics. The rates of metabolic syndrome for patients taking lurasidone are comparable to placebo groups. Lurasidone is a safe and effective treatment for patients with acute schizophrenia and bipolar depression. .. …
It has rapid absorption and linear pharmacokinetics. The rates of metabolic syndrome for patients taking lurasidone are comparable to …
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Keramatian K, Chakrabarty T, DuBow A, Saraf G, Yatham LN. Keramatian K, et al. Drugs. 2023 Jul;83(10):843-863. doi: 10.1007/s40265-023-01872-x. Epub 2023 May 25. Drugs. 2023. PMID: 37227597 Review.
Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primary driver of functional impairment and suicidality in BD. ...Included are new atypical anti-psychotics, glutamate modulators (ketamine and cy …
Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primar …
[Mood Stabilizers: An Overview].
Suzuki E. Suzuki E. Brain Nerve. 2023 May;75(5):605-611. doi: 10.11477/mf.1416202386. Brain Nerve. 2023. PMID: 37194539 Japanese.
Bipolar disorder, a mental illness that affects mood, behavior, and motivation is characterized by alternating depressive and manic (hypomanic) episodes (some mixed episodes include both types of symptoms), with periods of remission between episodes. ...Classically, lithiu …
Bipolar disorder, a mental illness that affects mood, behavior, and motivation is characterized by alternating depressive and manic ( …
A Case Report of Sinus Bradycardia after the Addition of Lurasidone in a Patient with Bipolar Disorder.
Kuang Q, Zhou S, She S, Zheng Y. Kuang Q, et al. Clin Psychopharmacol Neurosci. 2023 May 30;21(2):395-399. doi: 10.9758/cpn.2023.21.2.395. Clin Psychopharmacol Neurosci. 2023. PMID: 37119233 Free PMC article.
The aim of this study was to report a case of sinus bradycardia caused by the addition of lurasidone. The patient, a 46-year-old bipolar disorder female, was admitted to the Affiliated Brain Hospital of Guangzhou Medical University with 28 years of alternating eupho …
The aim of this study was to report a case of sinus bradycardia caused by the addition of lurasidone. The patient, a 46-year-old b …
Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia.
Janas-Kozik M, Dudek D, Heitzman J, Remberk B, Samochowiec J, Słopień A, Wichniak A. Janas-Kozik M, et al. Psychiatr Pol. 2022 Aug 31;56(4):675-695. doi: 10.12740/PP/OnlineFirst/149707. Epub 2022 Aug 31. Psychiatr Pol. 2022. PMID: 37074823 Free article. English, Polish.
Early-onset schizophrenia must be thoroughly differentiated from uni - or bipolar affective disorder, autism-spectrum disorders (ASDs) and anxiety disorder. ...Second-generation antipsychotic agents approved for the treatment of early-onset schizophrenia - aripiprazole, …
Early-onset schizophrenia must be thoroughly differentiated from uni - or bipolar affective disorder, autism-spectrum disorders (ASDs …
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data.
Fountoulakis KN, Ioannou M, Tohen M, Haarman BCM, Zarate CA Jr. Fountoulakis KN, et al. Eur Neuropsychopharmacol. 2023 Jul;72:30-39. doi: 10.1016/j.euroneuro.2023.03.009. Epub 2023 Apr 14. Eur Neuropsychopharmacol. 2023. PMID: 37060629 Free article. Review.
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. ...The neurobiology of bipolar depression and the possible targets of bipolar antidepressant therapy remain elusive. ...
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. ...The neurobiology of bipola …
Application of Antipsychotic Drugs in Mood Disorders.
Rybakowski JK. Rybakowski JK. Brain Sci. 2023 Feb 27;13(3):414. doi: 10.3390/brainsci13030414. Brain Sci. 2023. PMID: 36979224 Free PMC article. Review.
The second-generation, so-called atypical antipsychotics (SGAs), such as clozapine, risperidone, olanzapine, and quetiapine, have antimanic activity and are also effective for the maintenance treatment of bipolar disorder. Additionally, quetiapine exerts therapeutic action …
The second-generation, so-called atypical antipsychotics (SGAs), such as clozapine, risperidone, olanzapine, and quetiapine, have antimanic …
Risperidone-Induced Sexual Dysfunction Case Report.
Cichon GJ, Qadri SF. Cichon GJ, et al. Cureus. 2023 Feb 23;15(2):e35357. doi: 10.7759/cureus.35357. eCollection 2023 Feb. Cureus. 2023. PMID: 36974234 Free PMC article.
In this case report, we present a 55-year-old male patient with a history of bipolar disorder type 1 who was admitted to an inpatient psychiatric facility due to a severe manic episode with psychotic features. The patient reported having previously taken risperidone for hi …
In this case report, we present a 55-year-old male patient with a history of bipolar disorder type 1 who was admitted to an inpatient …
Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression.
Tocco M, Newcomer JW, Mao Y, Pikalov A. Tocco M, et al. CNS Spectr. 2023 Dec;28(6):680-687. doi: 10.1017/S1092852923001190. Epub 2023 Mar 24. CNS Spectr. 2023. PMID: 36961124 Clinical Trial.
This post hoc analysis assessed the effect of treatment with lurasidone on risk of MetS in patients with bipolar depression. METHODS: Data used in the current analyses consisted of 3 double-blind (DB), placebo-controlled, 6-week studies in adults with bipolar …
This post hoc analysis assessed the effect of treatment with lurasidone on risk of MetS in patients with bipolar depression. M …
Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review.
Cai L, Chen G, Yang H, Bai Y. Cai L, et al. Int Clin Psychopharmacol. 2023 Jul 1;38(4):249-260. doi: 10.1097/YIC.0000000000000449. Epub 2023 Mar 13. Int Clin Psychopharmacol. 2023. PMID: 36947416
The whole picture of psychotropics for bipolar depression (BPD) remains unclear. This review compares the differences in efficacy and safety profiles among common psychotropics for BPD. ...Cariprazine and aripiprazole seemed to be associated with an increased risk of akath …
The whole picture of psychotropics for bipolar depression (BPD) remains unclear. This review compares the differences in efficacy and …
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder.
Johnson DE, McIntyre RS, Mansur RB, Rosenblat JD. Johnson DE, et al. Expert Opin Pharmacother. 2023 Apr;24(5):641-654. doi: 10.1080/14656566.2023.2194488. Epub 2023 Mar 24. Expert Opin Pharmacother. 2023. PMID: 36946229 Review.
INTRODUCTION: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optimal socio-occupational functioning and reducing quality of life. ...AREAS COVERED: This review summarizes the available evidence for pharmaco …
INTRODUCTION: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optim …
Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report.
Ricci V, Di Salvo G, Maina G. Ricci V, et al. Int Clin Psychopharmacol. 2023 Jul 1;38(4):275-280. doi: 10.1097/YIC.0000000000000465. Epub 2023 Feb 27. Int Clin Psychopharmacol. 2023. PMID: 36853746
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. ...Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms....
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. ...Lurasidone …
Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 update.
Cheng CM, Chang WH, Lin YT, Chen PS, Yang YK, Bai YM; TSBPN Bipolar Taskforce. Cheng CM, et al. Asian J Psychiatr. 2023 Apr;82:103480. doi: 10.1016/j.ajp.2023.103480. Epub 2023 Jan 24. Asian J Psychiatr. 2023. PMID: 36724568 Free article. Review.
The complexity of treating patients with bipolar disorder prompted the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) to publish the first Taiwan consensus on pharmacological treatment of bipolar disorders in 2012. ...It may facilitat …
The complexity of treating patients with bipolar disorder prompted the Taiwanese Society of Biological Psychiatry and Neuropsychophar …
Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications.
Cohen LS, Church TR, Freeman MP, Gaccione P, Caplin PS, Kobylski LA, Arakelian M, Rossa ET, Chitayat D, Hernández-Díaz S, Viguera AC. Cohen LS, et al. J Womens Health (Larchmt). 2023 Apr;32(4):452-462. doi: 10.1089/jwh.2022.0310. Epub 2023 Jan 30. J Womens Health (Larchmt). 2023. PMID: 36716275
Participants were predominantly White, college-educated, and married (lurasidone = 88.1%, 76.9%, 77.6%; quetiapine = 89.8%, 71.2%, 75.0%; controls = 92.7%, 86.7%, 89.1%). Absolute risks of major malformations were 2.19% (lurasidone), 1.85% (quetiapine), and 1.77% (c …
Participants were predominantly White, college-educated, and married (lurasidone = 88.1%, 76.9%, 77.6%; quetiapine = 89.8%, 71.2%, 75 …
Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-beta-cyclodextrin.
Gamboa-Arancibia ME, Caro N, Gamboa A, Morales JO, González Casanova JE, Rojas Gómez DM, Miranda-Rojas S. Gamboa-Arancibia ME, et al. Pharmaceutics. 2023 Jan 10;15(1):232. doi: 10.3390/pharmaceutics15010232. Pharmaceutics. 2023. PMID: 36678861 Free PMC article.
Most of the new drugs developed for common pathologies present solubility issues. This is the case of lurasidone hydrochloride-a drug used for the treatment of schizophrenia and bipolar depression. ...Herein, we propose to study the increase in the solubility …
Most of the new drugs developed for common pathologies present solubility issues. This is the case of lurasidone hydrochloride …
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression.
Kishi T, Nakamura H, Kato T, Iwata N. Kishi T, et al. Neuropsychopharmacol Rep. 2023 Mar;43(1):137-140. doi: 10.1002/npr2.12319. Epub 2023 Jan 12. Neuropsychopharmacol Rep. 2023. PMID: 36632763 Free PMC article. Clinical Trial.
INTRODUCTION: Kato et al. reported results of a 6-week, double-blind, randomized, placebo-controlled trial of lurasidone in adults with bipolar depression (BDep). AIM: We performed a post hoc analysis using data from the lurasidone trial to predict later resp …
INTRODUCTION: Kato et al. reported results of a 6-week, double-blind, randomized, placebo-controlled trial of lurasidone in adults wi …
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Ricci V, Martinotti G, De Berardis D, Maina G. Ricci V, et al. Int J Environ Res Public Health. 2022 Nov 30;19(23):16057. doi: 10.3390/ijerph192316057. Int J Environ Res Public Health. 2022. PMID: 36498129 Free PMC article.
Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or as adjunctive therapy with lithium or valproate. ...CONCLUSION: There are non-con …
Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disord …
Psychopharmacological Treatment Algorithms of Manic/Mixed and Depressed Episodes in Pediatric Bipolar Disorder.
Hobbs E, Reed R, Lorberg B, Robb AS, Dorfman J. Hobbs E, et al. J Child Adolesc Psychopharmacol. 2022 Dec;32(10):507-521. doi: 10.1089/cap.2022.0035. Epub 2022 Dec 2. J Child Adolesc Psychopharmacol. 2022. PMID: 36472471 Review.
Introduction: Pediatric bipolar disorder (PBD) is a severe psychiatric illness diagnosed before the age of 18, which is associated with extreme shifts in mood characterized by manic and depressive episodes. ...Conclusions: We offer an update to the 2005 AACAP algorithms fo …
Introduction: Pediatric bipolar disorder (PBD) is a severe psychiatric illness diagnosed before the age of 18, which is associated wi …
Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study.
Diao X, Luo D, Wang D, Lai J, Li Q, Zhang P, Huang H, Wu L, Lu S, Hu S. Diao X, et al. Pharmaceuticals (Basel). 2022 Nov 14;15(11):1403. doi: 10.3390/ph15111403. Pharmaceuticals (Basel). 2022. PMID: 36422533 Free PMC article.
The clinical efficacy of lurasidone and quetiapine, two commonly prescribed atypical antipsychotics for bipolar depression, has been inadequately studied in young patients. ...However, the quetiapine group presented a more apparent change in body weight than the …
The clinical efficacy of lurasidone and quetiapine, two commonly prescribed atypical antipsychotics for bipolar depression, ha …
Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression.
Singh MK, Siu C, Tocco M, Pikalov A, Loebel A. Singh MK, et al. Curr Neuropharmacol. 2023;21(6):1393-1404. doi: 10.2174/1570159X20666220927112625. Curr Neuropharmacol. 2023. PMID: 36173066 Free PMC article. Clinical Trial.
BACKGROUND: The presence of mixed (subsyndromal hypomanic) symptoms may influence treatment outcomes in pediatric bipolar depression. This post-hoc analysis investigated "bridge" symptoms that have cross-sectional and predictive associations with depressive and manic sympt …
BACKGROUND: The presence of mixed (subsyndromal hypomanic) symptoms may influence treatment outcomes in pediatric bipolar depression. …
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
Croatto G, Vancampfort D, Miola A, Olivola M, Fiedorowicz JG, Firth J, Alexinschi O, Gaina MA, Makkai V, Soares FC, Cavaliere L, Vianello G, Stubbs B, Fusar-Poli P, Carvalho AF, Vieta E, Cortese S, Shin JI, Correll CU, Solmi M. Croatto G, et al. Mol Psychiatry. 2023 Jan;28(1):369-390. doi: 10.1038/s41380-022-01770-w. Epub 2022 Sep 22. Mol Psychiatry. 2023. PMID: 36138129 Free PMC article.
In adults with bipolar disorder, olanzapine worsened HbA1c/TC/WG (moderate/large ES); asenapine increased fasting glucose (small ES); quetiapine/cariprazine/risperidone induced WG (small/moderate ES). In bipolar depression, lurasidone was metabolically neutra …
In adults with bipolar disorder, olanzapine worsened HbA1c/TC/WG (moderate/large ES); asenapine increased fasting glucose (small ES); …
Diagnosis and Treatment of Bipolar Illness in the Primary Care Office.
Brieler JA, Keegan-Garrett E. Brieler JA, et al. Mo Med. 2022 May-Jun;119(3):213-218. Mo Med. 2022. PMID: 36035565 Free PMC article.
Appreciation for the range of bipolar illness has evolved in recent years, and the overlap of bipolar illness with trauma-based diagnosis such as Post-Traumatic Stress Disorder (PTSD) and Borderline Personality Disorder must be considered. ...First line agents for d …
Appreciation for the range of bipolar illness has evolved in recent years, and the overlap of bipolar illness with trauma-base …
Impact of Lurasidone on Metabolic Parameters and Prolactin Levels Based on Differences of Psychiatric Diagnosis, Dosage, and Introducing Methods: An Observational Study.
Nakamura M, Nagamine T. Nakamura M, et al. Innov Clin Neurosci. 2022 Apr-Jun;19(4-6):70-77. Innov Clin Neurosci. 2022. PMID: 35958975 Free PMC article.
However, evidence on lurasidone is limited in psychiatric clinical settings. This study aimed to investigate the effect of short-term lurasidone treatment on metabolic effects and prolactin (PRL) levels, in relation to the differences of psychiatric disorders, lu …
However, evidence on lurasidone is limited in psychiatric clinical settings. This study aimed to investigate the effect of short-term …
Lumateperone (Caplyta) for bipolar depression.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 Aug 8;64(1656):126-128. Med Lett Drugs Ther. 2022. PMID: 35921078 No abstract available.
Effectiveness and Tolerability of Lurasidone for Bipolar Types I and II and Other Specified Bipolar Depression: A 12-Week Observational Study.
Takaesu Y, Takeshima M, Watanabe K. Takaesu Y, et al. J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):485-488. doi: 10.1097/JCP.0000000000001590. Epub 2022 Aug 2. J Clin Psychopharmacol. 2022. PMID: 35916577
BACKGROUND: There are few guidelines on the management of depressive episodes in patients with bipolar type II (BDII) and related disorders (other specified bipolar and related disorders [OSBD]). ...This retrospective chart review study aimed to examine the effectiv …
BACKGROUND: There are few guidelines on the management of depressive episodes in patients with bipolar type II (BDII) and related dis …
Neurocognitive functioning in bipolar disorder: What we know and what we don't.
Keramatian K, Torres IJ, Yatham LN. Keramatian K, et al. Dialogues Clin Neurosci. 2022 Jun 1;23(1):29-38. doi: 10.1080/19585969.2022.2042164. eCollection 2021. Dialogues Clin Neurosci. 2022. PMID: 35860174 Free PMC article. Review.
Introduction: This narrative review of systematic reviews and meta-analyses aims at compiling available evidence in various aspects of neurocognitive functioning in Bipolar Disorder (BD). Methods: We conducted a MEDLINE literature search and identified 38 relevant systemat …
Introduction: This narrative review of systematic reviews and meta-analyses aims at compiling available evidence in various aspects of neuro …
Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O. Vasiliu O. Front Pharmacol. 2022 Jun 17;13:884155. doi: 10.3389/fphar.2022.884155. eCollection 2022. Front Pharmacol. 2022. PMID: 35847011 Free PMC article.
Many investigational drugs with antidepressant activity are currently explored in different phases of clinical research, with indications such as major depressive disorder, treatment-resistant major depression, bipolar depression, post-partum depression, and late-life depr …
Many investigational drugs with antidepressant activity are currently explored in different phases of clinical research, with indications su …
Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical-mediated oxidative and photolytic conditions via liquid chromatography-photodiode array/ultraviolet-tandem mass spectrometry and one-dimensional/two-dimensional nuclear magnetic resonance spectroscopy.
Wang KC, Guo Q, Kuang Z, Jin J, Li D, Chen W, Zhu W, Li M. Wang KC, et al. J Mass Spectrom. 2022 Jul;57(7):e4871. doi: 10.1002/jms.4871. J Mass Spectrom. 2022. PMID: 35739062
Lurasidone is an antipsychotic drug clinically used for the treatment of schizophrenia and bipolar disorder. ...The degradant observed under the solution photolytic condition is identified as the photo-induced isomer of lurasidone with the benzisothiazole rin …
Lurasidone is an antipsychotic drug clinically used for the treatment of schizophrenia and bipolar disorder. ...The degradant …
261 results

Searches related to "lurasidone bipolar"